Science Explorer Back to mapMap
Discussion
Topic · Rheumatology

Eosinophilic Disorders and Syndromes

Eosinophilic Disorders and Syndromes is a research topic within Rheumatology. Science Explorer counts 30k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the hypereosinophilic syndrome and related disorders, including the molecular pathogenesis, classification, and therapeutic management. It covers topics such as fusion genes (e.g., FIP1L1-PDGFRA), imatinib mesylate treatment, cardiac manifestations, and the classification of eosinophilic disorders.

  • Hypereosinophilic Syndrome
  • Fusion Genes
  • Imatinib Mesylate
  • Eosinophilia
  • PDGFRA
  • Classification
  • Molecular Pathogenesis
  • Cardiac Manifestations
  • Therapeutic Management
  • Eosinophilic Disorders
Research works
30k
fractional, since 1950
In the world top 10%
3.1k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+7%
the tick is no change
Largest producer
United States
38% of the 10 largest, 2022-now
Eosinophilic Disorders and Syndromes

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Eosinophilic Disorders and Syndromes research?

By volume, the United States and China publish the most (1.5k and 535 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.5k works
  2. 2 China 535 works
  3. 3 Japan 389 works
  4. 4 Italy 293 works
  5. 5 India 289 works
  6. 6 Spain 196 works
  7. 7 Germany 196 works
  8. 8 United Kingdom 182 works
  9. 9 France 180 works
  10. 10 Brazil 131 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 38.3%China: 13.8%Japan: 10.0%Italy: 7.6%6 others listed: 30.3%38%largest
United States1,484 · 38.3%China535 · 13.8%Japan389 · 10.0%Italy293 · 7.6%6 others listed1,174 · 30.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Eosinophilic Disorders and Syndromes research?

By volume in 2022-now, Mayo Clinic publishes the most Eosinophilic Disorders and Syndromes research, followed by Harvard University and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 Mayo ClinicUnited States 54 works
  2. 2 Harvard UniversityUnited States 51 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 30 works
  4. 4 All India Institute of Medical SciencesIndia 27 works
  5. 5 University of CincinnatiUnited States 26 works
  6. 6 Université Paris CitéFrance 25 works
  7. 7 InsermFrance 25 works
  8. 8 The University of Texas MD Anderson Cancer CenterUnited States 24 works
  9. 9 University of North Carolina at Chapel HillUnited States 23 works
  10. 10 National Institutes of HealthUnited States 23 works

Who are the leading researchers in Eosinophilic Disorders and Syndromes?

The most-cited researchers publishing on Eosinophilic Disorders and Syndromes include Guido Kroemer, Jun Wang and Gregory Y.H. Lip.

  1. 1 Guido Kroemer France 386k citations
  2. 2 Jun Wang China 340k citations
  3. 3 Gregory Y.H. Lip United Kingdom 311k citations
  4. 4 Todd R. Golub United States 283k citations
  5. 5 Hagop M. Kantarjian United States 273k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Eosinophilic Disorders and Syndromes?

The most cited paper in Eosinophilic Disorders and Syndromes is "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" (Brian J. Druker, Moshe Talpaz, Debra J. Resta et al., 2001), with 5,296 citations. Next come "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells" (3,681) and "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" (3,593).

Most cited papers
#PaperReleasedCitations
1 Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Brian J. Druker, Moshe Talpaz, Debra J. Resta et al. · New England Journal of Medicine Open access 5 Apr 2001 5,296
2 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells Brian J. Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine May 1996 3,681
3 Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Stephen G. O’Brien et al. · New England Journal of Medicine Open access 12 Mar 2003 3,593
4 Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Brian J. Druker et al. · New England Journal of Medicine Open access 6 Dec 2006 3,508
5 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Ross L. Levine et al. · Cancer Cell Open access Apr 2005 3,023
All 100 most cited papers, with filters and sorting

Where is Eosinophilic Disorders and Syndromes research done?

The largest centres of Eosinophilic Disorders and Syndromes research in 2022-now are Beijing (China), Tokyo (Japan), New York (United States) and London (United Kingdom). Among places with at least 20 works in it, it is an unusually large share of all research in Scottsdale.

Largest cities, 2022-now

  1. 1 BeijingChina 96 works
  2. 2 TokyoJapan 89 works
  3. 3 New YorkUnited States 78 works
  4. 4 LondonUnited Kingdom 73 works
  5. 5 ParisFrance 70 works
  6. 6 PhiladelphiaUnited States 58 works
  7. 7 BostonUnited States 50 works
  8. 8 RomeItaly 48 works
  9. 9 HoustonUnited States 47 works
  10. 10 MadridSpain 44 works

Where it is the local speciality

  1. ScottsdaleUS · 20.6 works8.1×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Eosinophilic Disorders and Syndromes than the world average.

See Eosinophilic Disorders and Syndromes on the map

Where is the best place to study Eosinophilic Disorders and Syndromes?

Among universities, judged by research, Harvard University, University of Padua and University of Cincinnati score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 20.21%fractional works in this field (log) →share of work in the world top 10% →University of North …University of PaduaHarvard UniversityUniversity of Cincin…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 76.924.2%3.5×51 +0.4%
2University of PaduaItaly 66.926.0%5.2×19 +133.8%
3University of CincinnatiUnited States 66.223.9%9.5×26 -13.0%
4University of North Carolina at Chapel HillUnited States 61.932.3%2.9×23 -26.4%
5Johns Hopkins UniversityUnited States 60.421.6%2.9×20 +13.0%
6Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 52.111.4%6.2×30 +26.9%
7Université Paris CitéFrance 51.314.5%7.4×26 -11.7%
8Cornell UniversityUnited States 50.911.0%3.7×22 +61.6%
9University of PennsylvaniaUnited States 50.019.2%4.3×21 -4.4%
10University College LondonUnited Kingdom 49.918.0%2.0×15 +13.8%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Eosinophilic Disorders and Syndromes, country by country

Is Eosinophilic Disorders and Syndromes research growing?

Output in 2022-2025 was 7% higher than in 2018-2021, peaking in 2023. The fastest-growing topics are Eosinophilic Disorders and Syndromes.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Eosinophilic Disorders and Syndromes as a percentage of every work published that year, 0.023% in 2024.

still counting0.020%0.040%0.060%Eosinophilic Disorders and Syndromes0.020% in 202519801990200020102020

Fractional works of Eosinophilic Disorders and Syndromes over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Eosinophilic Disorders and Syndromes10.2% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Eosinophilic Disorders and Syndromes. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.